Research Output Journal of Engineering and Scientific Research 5(1): 9-13, 2026

ROJESR Publications Online ISSN: 1115-9790

https://rojournals.org/roj-engineering-and-scientific-research/ Print ISSN: 1115-6155

https://doi.org/10.59298/ROJESR/2026/5.1913

PPAR-Gamma Selective Modulators for Insulin Resistance: Metabolic Outcomes Without Thiazolidinedione Adverse Effects

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Peroxisome proliferator-activated receptor gamma (PPAR-γ) played a central role in regulating glucose and lipid metabolism, making it a critical target for combating insulin resistance and type 2 diabetes mellitus. Traditional PPAR-γ agonists, notably thiazolidinediones (TZDs), effectively improved insulin sensitivity but were limited by adverse effects such as weight gain, edema, and cardiovascular risks. Recent developments focus on synthetic PPAR-γ modulators that selectively activate beneficial pathways while minimizing harmful side effects. This review aimed to critically evaluate the molecular mechanisms of selective PPAR-γ modulators (SPARMs), their impact on metabolic outcomes, and their potential to overcome adverse effects associated with TZDs. An extensive literature search identified preclinical and clinical studies assessing the efficacy and safety profiles of SPARMs, with inclusion criteria emphasizing mechanistic insights and metabolic endpoints. Emerging evidence indicated that SPARMs induced favorable improvements in insulin sensitivity, lipid profiles, and inflammatory markers comparable to TZDs but with reduced or absent adverse effects such as weight gain and edema. Structural modifications that influenced coactivator recruitment appeared pivotal for these outcomes. However, variability in clinical responses and limited long-term data highlight ongoing challenges. Selective PPAR-γ modulators held promise as therapeutic agents capable of delivering metabolic benefits without the adverse effects characteristic of TZDs. Nonetheless, further detailed mechanistic studies and extended clinical assessments were required to fully delineate their safety and efficacy profiles.

Keywords: PPAR-gamma, Selective modulators, Insulin resistance, Metabolic outcomes, Thiazolidinediones.

INTRODUCTION

Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a ligand-activated nuclear receptor belonging to the nuclear hormone receptor superfamily [1, 2]. It functions as a transcription factor regulating gene expression involved in adipogenesis, lipid storage, glucose homeostasis, and anti-inflammatory responses. Expressed predominantly in adipose tissue, PPAR-γ modulates the differentiation of preadipocytes into mature adipocytes, leading to improved lipid buffering and insulin sensitivity [3, 4]. Its molecular activity is influenced by endogenous ligands such as fatty acids and eicosanoids, as well as synthetic compounds designed to activate or modulate its activity. The affinity of various ligands for PPAR-γ depends on their chemical structure, and their interaction with the receptor's ligand-binding domain influences the recruitment of coactivators or corepressors, ultimately shaping gene expression profiles [5]. Understanding these biochemical pathways is critical for designing targeted modulators with therapeutic potential in metabolic diseases.

Insulin resistance, a hallmark of metabolic syndrome and type 2 diabetes mellitus, is characterized by impaired cellular response to insulin, leading to hyperglycemia [6–8]. PPAR-γ influences insulin sensitivity primarily

through its effects on adipocyte function and systemic lipid distribution; activation improves glucose uptake, reduces circulating free fatty acids, and modulates inflammatory cytokine expression. TZDs full PPAR-γ agonists have demonstrated significant efficacy in lowering blood glucose levels and enhancing insulin action [9]. However, despite these benefits, their clinical use is curtailed by adverse effects including weight gain, fluid retention, and increased cardiovascular risk, thought to result from broad receptor activation. Consequently, the development of PPAR-γ modulators that selectively activate downstream pathways responsible for insulin-sensitizing effects while avoiding pathways leading to side effects has become an area of intense investigation. The challenge lies in delineating signaling cascades and structural modifications that permit such selectivity, aiming to create safer, more effective therapies. This review synthesizes current understanding of the molecular mechanisms guiding selective PPAR-γ modulation, evaluates evidence from preclinical and clinical studies on metabolic outcomes, and discusses prospects for clinical translation to improve insulin sensitivity with minimal adverse effects.

MOLECULAR MECHANISM AND BIOCHEMISTRY OF PPAR-Γ MODULATORS

PPAR-γ activity is modulated by ligand binding, leading to conformational changes that influence coactivator or corepressor recruitment [10, 11]. Full agonists like TZDs induce a stable receptor conformation favoring coactivator association, resulting in broad activation of target genes [12]. In contrast, selective modulators are designed to induce partial agonism or biased signaling, favoring beneficial gene expression profiles while impairing pathways associated with adverse effects. The structural basis relies on specific ligand-receptor interactions within the ligand-binding domain, which can be informed by structure-activity relationship analyses and crystallography studies. Selective PPAR-γ modulators (SPARMs) typically exhibit altered interactions with amino acid residues in the binding pocket, which influence coactivator recruitment selectively, leading to differential gene expression [13, 14].

The downstream signaling cascades activated by PPAR-γ influence multiple metabolic pathways. Beneficial effects include upregulation of genes involved in glucose transporter activity, fat storage, and anti-inflammatory responses. Conversely, pathways associated with fluid retention and weight gain involve different coactivator complexes and gene networks. Selective modulation aims to suppress or avoid the activation of pathways leading to these side effects, thus providing metabolic benefits while reducing toxicity. For instance, SPARMs may preferentially activate pathways linked to adipocyte insulin sensitivity without promoting excessive adipogenesis or fluid retention a delicate balance that remains under investigation [15].

Designing effective SPARMs involves modifying the chemical structure to influence receptor conformation and coactivator interactions. Structural features such as the ligand's shape, polarity, and binding affinity dictate the receptor's conformational state, influencing selective gene activation [16]. These design principles are informed by high-resolution receptor-ligand crystal structures and computational modeling, aiming to optimize selectivity and pharmacokinetics.

ANALYTICAL AND EXPERIMENTAL METHODS

The investigation of PPAR-γ modulators relies heavily on structural biology techniques, including X-ray crystallography and nuclear magnetic resonance spectroscopy, to characterize ligand-receptor interactions [17]. Reporter gene assays measure the transcriptional activity of PPAR-γ in response to various ligands, while coactivator recruitment assays (such as fluorescence resonance energy transfer) assess ligand-induced conformational shifts [18–20]. These biochemical methods reveal the differential activation profiles of SPARMs compared to full agonists.

In vivo studies primarily utilize rodent models of insulin resistance, obesity, and type 2 diabetes to assess the metabolic effects of PPAR-γ modulating compounds [21]. Parameters evaluated include blood glucose levels, insulin sensitivity indices, lipid profiles, and body weight. Clinical studies extend these assessments to human subjects, incorporating measurements of HbA1c, fasting glucose, lipid levels, and body composition [22]. Safety evaluations monitor adverse events linked to fluid retention, weight gain, and cardiovascular parameters. Pharmacokinetic profiling provides insights into the duration and intensity of receptor activation, informing dosing strategies.

Current assays may not fully recapitulate the complexity of systemic metabolism or the tissue-specific actions of PPAR-γ modulators. The limited availability of long-term human data also restricts definitive conclusions on safety profiles and the durability of metabolic improvements induced by SPARMs.

CLINICAL AND PATHOPHYSIOLOGICAL IMPLICATIONS

Clinical evidence suggests that selective PPAR-γ modulators can improve insulin sensitivity comparable to TZDs but with fewer side effects [23]. Patients treated with these agents exhibit reductions in fasting glucose, HbA1c, and triglycerides, alongside increases in HDL cholesterol. The modulation of gene expression in adipose tissue correlates with enhanced insulin signaling and reduced inflammatory cytokines, elucidating their mechanistic benefits in metabolic regulation.

PPAR-γ exerts anti-inflammatory effects through transrepression of proinflammatory transcription factors, such as NF-κB. Selective modulators enhance these properties without activating pathways responsible for weight gain and fluid retention [24]. Additionally, modulation of adipocyte differentiation and lipid storage capacity contributes to improved metabolic flexibility.

The therapeutic application extends beyond type 2 diabetes to metabolic syndrome-related cardiovascular complications, fatty liver disease, and obesity. The influence of PPAR-γ modulators on end-organ effects and inflammatory processes influences disease progression and complication risk.

THERAPEUTIC AND TRANSLATIONAL PROSPECTS

Recent structural insights have enabled the rational design of SPARMs with tailored receptor binding properties. Hybrid compounds with biased agonism demonstrate promising efficacy in preclinical studies. These novel agents aim to maximize insulin-sensitizing effects while minimizing safety concerns, representing a potential paradigm shift from traditional TZDs.

Emerging clinical data support the safety advantages of SPARMs. Nonetheless, heterogeneity in patient responses and limited long-term data pose challenges for regulatory approval and widespread adoption [25, 26]. Combination therapies targeting multiple pathways may offer additional benefits.

The complexity of PPAR-γ signaling warrants further elucidation of tissue-specific effects and cofactor interactions [27]. Biomarker development for predicting response and adverse effects is crucial. Long-term, large-scale randomized controlled trials are necessary to confirm efficacy and safety, as well as to determine optimal dosing strategies.

GAPS, CONTROVERSIES, AND FUTURE RESEARCH

Despite promising developments, several uncertainties remain. The precise molecular basis for the differential recruitment of cofactors by SPARMs requires further clarification. Some studies show inconsistent metabolic benefits or raise safety concerns, necessitating rigorous validation. Additionally, the interplay between PPAR-γ and other nuclear receptors complicates the understanding of systemic effects [28, 29]. Future research should focus on identifying biomarkers for selectivity, exploring tissue-specific delivery systems, and long-term safety assessments.

CONCLUSION

Selective PPAR-gamma modulators represent a promising therapeutic approach for improving insulin sensitivity and metabolic health while circumventing adverse effects inherent to TZDs. The molecular design of these agents capitalizes on biased agonism and receptor conformational modulation, offering targeted gene regulation with a favorable safety profile. Although preclinical evidence supports their potential, clinical translation remains challenged by variability in patient responses and paucity of long-term data. Continued efforts in structural biology, pharmacology, and clinical research are essential to realize their full therapeutic promise. These efforts could significantly impact the management of insulin resistance and associated metabolic disorders, contributing to personalized medicine approaches and improved patient outcomes. Future research should prioritize long-term clinical trials to validate the safety and efficacy of selective PPAR-γ modulators in diverse patient populations.

REFERENCES

1. Tyagi, S., Gupta, P., Saini, A.S., Kaushal, C., Sharma, S.: The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. Journal of Advanced Pharmaceutical Technology & Research. 2, 236 (2011). https://doi.org/10.4103/2231-4040.90879
2. Subramani, P.A., Reddy, M.C., Narala, V.R.: The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands. Endocrine, Metabolic & Immune Disorders-Drug Targets. 13, 175–183 (2013). https://doi.org/10.2174/18715303113139990003
3. Xu, Y., Yu, T., Ma, G., Zheng, L., Jiang, X., Yang, F., Wang, Z., Li, N., He, Z., Song, X., Wen, D., Kong, J., Yu, Y., Cao, L.: Berberine modulates deacetylation of PPARγ to promote adipose tissue remodeling and thermogenesis via AMPK/SIRT1 pathway. International Journal of Biological Sciences. 17, 3173–3187 (2021). https://doi.org/10.7150/ijbs.62556
4. Moreno-Navarrete, J.M., Fernández-Real, J.M.: Adipocyte Differentiation. In: Symonds, M.E. (ed.) Adipose Tissue Biology. pp. 69–90. Springer International Publishing, Cham (2017)
5. Harmon, G.S., Lam, M.T., Glass, C.K.: PPARs and Lipid Ligands in Inflammation and Metabolism. Chem. Rev. 111, 6321–6340 (2011). https://doi.org/10.1021/cr2001355
6. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
7. Ugwu, O.P.C., Erisa, K., Raphael, I., Emmanuel I., O., Alum, E.U., Michael B, O., Subbarayan, S., Sankarapandiyan, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda:

Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR ES. 12, 214–224 (2023). https://doi.org/10.59298/INOSRES/2023/2.17.1000
8. Uti, D.E., Igile, G.O., Omang, W.A., Umoru, G.U., Udeozor, P.A., Obeten, U.N., Ogbonna, O.N., Ibiam, U.A., Alum, E.U., Opotu, Ohunene, R., Chukwufumnanya, M.J., Oplekwu, R.I., A, W., Obio: Anti-Diabetic Potentials Of Vernonioside E Saponin; A Biochemical Study. NVEO - NATURAL VOLATILES & ESSENTIAL OILS Journal | NVEO. 14234–14254 (2021)
9. S, R., S, C., Bhat, V.N., Haritas, A., T, D., Shivani, K.: Thiazolidinediones-PPAR-γ Agonists; for the treatment of Type II Diabetes Mellitus. Journal of Advanced Zoology. 45, 1 (2024)
10. Harmon, G.S., Lam, M.T., Glass, C.K.: PPARs and Lipid Ligands in Inflammation and Metabolism. Chem. Rev. 111, 6321–6340 (2011). https://doi.org/10.1021/cr2001355
11. Burns, K.A., Vanden Heuvel, J.P.: Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta. 1771, 952–960 (2007). https://doi.org/10.1016/j.bbalip.2007.04.018
12. Higashi, Y., Holder, K., Delafontaine, P.: Thiazolidinediones Up-regulate Insulin-like Growth Factor-1 Receptor via a Peroxisome Proliferator-activated Receptor γ-Independent Pathway. J Biol Chem. 285, 36361–36368 (2010). https://doi.org/10.1074/jbc.M110.137661
13. Govindarajulu, M., Pinky, P.D., Bloemer, J., Ghanei, N., Suppiramaniam, V., Amin, R.: Signaling Mechanisms of Selective PPARγ Modulators in Alzheimer's Disease. PPAR Research. 2018, 2010675 (2018). https://doi.org/10.1155/2018/2010675
14. Zhang, F., Lavan, B.E., Gregoire, F.M.: Selective Modulators of PPAR-γ Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res. 2007, 32696 (2007). https://doi.org/10.1155/2007/32696
15. Guilherme, A., Virbasius, J.V., Puri, V., Czech, M.P.: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 9, 367–377 (2008). https://doi.org/10.1038/nrm2391
16. Panday, S.K., Ghosh, I.: In Silico Structure-Based Prediction of Receptor–Ligand Binding Affinity: Current Progress and Challenges. In: Mohan, C.G. (ed.) Structural Bioinformatics: Applications in Preclinical Drug Discovery Process. pp. 109–175. Springer International Publishing, Cham (2019)
17. Falbo, E., Delre, P., Lavecchia, A.: From Apo to Ligand-Bound: Unraveling PPARγ-LBD Conformational Shifts via Advanced Molecular Dynamics. ACS Omega. 10, 13303–13318 (2025). https://doi.org/10.1021/acsomega.4c11128
18. Harmon, G.S., Lam, M.T., Glass, C.K.: PPARs and Lipid Ligands in Inflammation and Metabolism. Chem. Rev. 111, 6321–6340 (2011). https://doi.org/10.1021/cr2001355
19. Kamata, S., Honda, A., Kashiwagi, N., Shimamura, A., Yashiro, S., Komori, Y., Hosoda, A., Akahoshi, N., Ishii, I.: Different Coactivator Recruitment to Human PPARα/δ/γ Ligand-Binding Domains by Eight PPAR Agonists to Treat Nonalcoholic Fatty Liver Disease. Biomedicines. 12, 624 (2024). https://doi.org/10.3390/biomedicines12030624
20. King, J.L., Smithers, L., Vrielink, A., Lesterhuis, W.J., Piggott, M.J.: A New Era for PPARγ: Covalent Ligands and Therapeutic Applications. J. Med. Chem. 68, 23705–23750 (2025). https://doi.org/10.1021/acs.jmedchem.5c02192
21. Stalin, A., Stephen Irudayaraj, S., Ramesh Kumar, D., Balakrishna, K., Ignacimuthu, S., Al-Dhabi, N.A., Duraipandiyan, V.: Identifying potential PPARγ agonist/partial agonist from plant molecules to control type 2 diabetes using in silico and in vivo models. Med Chem Res. 25, 1980–1992 (2016). https://doi.org/10.1007/s00044-016-1621-z
22. Peng, W., Mao, P., Liu, L., Chen, K., Zhong, Y., Xia, W., Guo, Q., Tan, S.C., Rahmani, J., Kord Varkaneh, H., He, P.: Effect of carnosine supplementation on lipid profile, fasting blood glucose, HbA1C and insulin resistance: A systematic review and meta-analysis of long-term randomized controlled trials. Complementary Therapies in Medicine. 48, 102241 (2020). https://doi.org/10.1016/j.ctim.2019.102241
23. DePaoli, A.M., Higgins, L.S., Henry, R.R., Mantzoros, C., Dunn, F.L.: Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone? Diabetes Care. 37, 1918–1923 (2014). https://doi.org/10.2337/dc13-2480
24. Vetuschi, A., Pompili, S., Gaudio, E., Latella, G., Sferra, R.: PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD. Eur Rev Med Pharmacol Sci. 22, 8839–8848 (2018). https://doi.org/10.26355/eurrev_201812_16652
25. Le Sueur, H., Bruce, I.N., Geifman, N., on behalf of the MASTERPLANS Consortium: The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus. BMC Med Res Methodol. 20, 164 (2020). https://doi.org/10.1186/s12874-020-01057-0

26. Velummailum, R.R., McKibbon, C., Brenner, D.R., Stringer, E.A., Ekstrom, L., Dron, L.: Data Challenges for Externally Controlled Trials: Viewpoint. Journal of Medical Internet Research. 25, e43484 (2023). https://doi.org/10.2196/43484
27. Harmon, G.S., Lam, M.T., Glass, C.K.: PPARs and Lipid Ligands in Inflammation and Metabolism. Chem. Rev. 111, 6321–6340 (2011). https://doi.org/10.1021/cr2001355
28. Caioni, G., Viscido, A., d'Angelo, M., Panella, G., Castelli, V., Merola, C., Frieri, G., Latella, G., Cimini, A., Benedetti, E.: Inflammatory Bowel Disease: New Insights into the Interplay between Environmental Factors and PPARγ. International Journal of Molecular Sciences. 22, 985 (2021). https://doi.org/10.3390/ijms22030985
29. Harmon, G.S., Lam, M.T., Glass, C.K.: PPARs and Lipid Ligands in Inflammation and Metabolism. Chem. Rev. 111, 6321–6340 (2011). https://doi.org/10.1021/cr2001355

CITE AS: Mugisha Emmanuel K. (2026). PPAR-Gamma Selective Modulators for Insulin Resistance: Metabolic Outcomes Without Thiazolidinedione Adverse Effects. Research Output Journal of Engineering and Scientific Research 5(1): 9-13. https://doi.org/10.59298/ROJESR/2026/5.1913